肾癌腔静脉取栓术。肾切除术32例报告[j]。

IF 0.5 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL
Pablo A Rojas, Juan Cristóbal Bravo, Renato Navarro, Sofía Villagran, Álvaro Zúñiga, Pablo Troncoso, Pedro Becker, Eduardo Briceño, Ignacio F San Francisco
{"title":"肾癌腔静脉取栓术。肾切除术32例报告[j]。","authors":"Pablo A Rojas,&nbsp;Juan Cristóbal Bravo,&nbsp;Renato Navarro,&nbsp;Sofía Villagran,&nbsp;Álvaro Zúñiga,&nbsp;Pablo Troncoso,&nbsp;Pedro Becker,&nbsp;Eduardo Briceño,&nbsp;Ignacio F San Francisco","doi":"10.4067/S0034-98872022000800994","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Vena cava (VC) involvement in kidney tumors occurs in 4 to 10% of cases, and is associated with a higher mortality. Nephrectomy with thrombectomy of the VC, performed by a multidisciplinary team, improves survival.</p><p><strong>Aim: </strong>To report a series of consecutive nephrectomies with caval thrombectomy performed in an academic center.</p><p><strong>Patients and methods: </strong>We report 32 patients with cT3b and 3c renal tumors, who underwent radical nephrectomy with VC thrombectomy between 2001 and 2021. A descriptive analysis of clinical, surgical and pathological variables was performed. Overall survival (OS) and cancer-specific survival (CSS) was calculated using Kaplan-Meier curves.</p><p><strong>Results: </strong>The mean tumor size was 9.7 cm. According to Mayo classification 3/32 (9%) patients had a type I thrombus, 10/32 (31%) had a type II thrombus, 8/32 (25%) had a type III thrombus, and 5/32 (16%) had a type IV thrombus. The mean bleeding was 2000 cc. There was one intraoperative death. Nineteen percent of patients had complications >= 3 according to Clavien-Dindo classification. Reoperations occurred in 9%. Pre and postoperative creatinine levels were 1.17 and 1.91 mg/dl respectively (p < 0.01). Pre and postoperative Hematocrit levels were 47.9 and 31% respectively (p = 0.02). Sixty six percent of tumors were clear cell renal cancer, 9% were papillary and 3% were chromophobic. Mean OS was 10 months. Two-year SCE was 40%.</p><p><strong>Conclusions: </strong>Our results are similar to those reported elsewhere. Despite being an unusual pathology, the surgical technique has been improving, thanks to the multidisciplinary work of urologists and surgeons.</p>","PeriodicalId":21360,"journal":{"name":"Revista medica de Chile","volume":"150 8","pages":"994-999"},"PeriodicalIF":0.5000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Vena cava thrombectomy in kidney cancer. Report of 32 nephrectomies].\",\"authors\":\"Pablo A Rojas,&nbsp;Juan Cristóbal Bravo,&nbsp;Renato Navarro,&nbsp;Sofía Villagran,&nbsp;Álvaro Zúñiga,&nbsp;Pablo Troncoso,&nbsp;Pedro Becker,&nbsp;Eduardo Briceño,&nbsp;Ignacio F San Francisco\",\"doi\":\"10.4067/S0034-98872022000800994\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Vena cava (VC) involvement in kidney tumors occurs in 4 to 10% of cases, and is associated with a higher mortality. Nephrectomy with thrombectomy of the VC, performed by a multidisciplinary team, improves survival.</p><p><strong>Aim: </strong>To report a series of consecutive nephrectomies with caval thrombectomy performed in an academic center.</p><p><strong>Patients and methods: </strong>We report 32 patients with cT3b and 3c renal tumors, who underwent radical nephrectomy with VC thrombectomy between 2001 and 2021. A descriptive analysis of clinical, surgical and pathological variables was performed. Overall survival (OS) and cancer-specific survival (CSS) was calculated using Kaplan-Meier curves.</p><p><strong>Results: </strong>The mean tumor size was 9.7 cm. According to Mayo classification 3/32 (9%) patients had a type I thrombus, 10/32 (31%) had a type II thrombus, 8/32 (25%) had a type III thrombus, and 5/32 (16%) had a type IV thrombus. The mean bleeding was 2000 cc. There was one intraoperative death. Nineteen percent of patients had complications >= 3 according to Clavien-Dindo classification. Reoperations occurred in 9%. Pre and postoperative creatinine levels were 1.17 and 1.91 mg/dl respectively (p < 0.01). Pre and postoperative Hematocrit levels were 47.9 and 31% respectively (p = 0.02). Sixty six percent of tumors were clear cell renal cancer, 9% were papillary and 3% were chromophobic. Mean OS was 10 months. Two-year SCE was 40%.</p><p><strong>Conclusions: </strong>Our results are similar to those reported elsewhere. Despite being an unusual pathology, the surgical technique has been improving, thanks to the multidisciplinary work of urologists and surgeons.</p>\",\"PeriodicalId\":21360,\"journal\":{\"name\":\"Revista medica de Chile\",\"volume\":\"150 8\",\"pages\":\"994-999\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2022-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista medica de Chile\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4067/S0034-98872022000800994\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista medica de Chile","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4067/S0034-98872022000800994","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:肾肿瘤的腔静脉(VC)受累发生率为4%至10%,并与较高的死亡率相关。由多学科团队进行的肾切除术合并静脉血栓切除术可提高生存率。目的:报道在某学术中心进行的一系列连续肾切除术合并腔静脉血栓切除术。患者和方法:我们报告了32例cT3b和3c肾肿瘤患者,他们在2001年至2021年间接受了根治性肾切除术和VC血栓切除术。对临床、手术和病理变量进行描述性分析。采用Kaplan-Meier曲线计算总生存期(OS)和肿瘤特异性生存期(CSS)。结果:肿瘤平均大小9.7 cm。根据Mayo分类,3/32(9%)患者为I型血栓,10/32(31%)患者为II型血栓,8/32(25%)患者为III型血栓,5/32(16%)患者为IV型血栓。平均出血2000毫升,术中死亡1例。根据Clavien-Dindo分类,19%的患者出现并发症>= 3。再手术发生率为9%。术前和术后肌酐水平分别为1.17和1.91 mg/dl (p < 0.01)。术前和术后红细胞压积分别为47.9%和31% (p = 0.02)。66%的肿瘤为透明细胞肾癌,9%为乳头状癌,3%为嗜色性肾癌。平均OS为10个月。两年SCE为40%。结论:我们的结果与其他地方报道的结果相似。尽管是一种不寻常的病理,由于泌尿科医生和外科医生的多学科工作,手术技术一直在改进。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Vena cava thrombectomy in kidney cancer. Report of 32 nephrectomies].

Background: Vena cava (VC) involvement in kidney tumors occurs in 4 to 10% of cases, and is associated with a higher mortality. Nephrectomy with thrombectomy of the VC, performed by a multidisciplinary team, improves survival.

Aim: To report a series of consecutive nephrectomies with caval thrombectomy performed in an academic center.

Patients and methods: We report 32 patients with cT3b and 3c renal tumors, who underwent radical nephrectomy with VC thrombectomy between 2001 and 2021. A descriptive analysis of clinical, surgical and pathological variables was performed. Overall survival (OS) and cancer-specific survival (CSS) was calculated using Kaplan-Meier curves.

Results: The mean tumor size was 9.7 cm. According to Mayo classification 3/32 (9%) patients had a type I thrombus, 10/32 (31%) had a type II thrombus, 8/32 (25%) had a type III thrombus, and 5/32 (16%) had a type IV thrombus. The mean bleeding was 2000 cc. There was one intraoperative death. Nineteen percent of patients had complications >= 3 according to Clavien-Dindo classification. Reoperations occurred in 9%. Pre and postoperative creatinine levels were 1.17 and 1.91 mg/dl respectively (p < 0.01). Pre and postoperative Hematocrit levels were 47.9 and 31% respectively (p = 0.02). Sixty six percent of tumors were clear cell renal cancer, 9% were papillary and 3% were chromophobic. Mean OS was 10 months. Two-year SCE was 40%.

Conclusions: Our results are similar to those reported elsewhere. Despite being an unusual pathology, the surgical technique has been improving, thanks to the multidisciplinary work of urologists and surgeons.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Revista medica de Chile
Revista medica de Chile 医学-医学:内科
CiteScore
1.20
自引率
16.70%
发文量
75
审稿时长
3-6 weeks
期刊介绍: La Revista Médica de Chile publica trabajos originales sobre temas de interés médico y de Ciencias Biomédicas, dando preferencia a los relacionados con la Medicina Interna y sus especialidades derivadas. Publicada mensualmente, desde 1872, por la Sociedad Médica de Santiago. La abreviatura de su título es Rev Med Chile, que debe ser usado en bibliografías, notas al pié de página, leyendas y referencias bibliográficas.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信